ASIERIS PHARMACEUTICALS
Asieris Pharmaceuticals is a Chinese biotech company focusing on therapeutic areas in oncology and multidrug-resistant infections.
ASIERIS PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2010-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.asieris.com
Total Employee:
251+
Status:
Active
Contact:
+86 21-68585280-606
Email Addresses:
[email protected]
Total Funding:
1.19 B CNY
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Global Site Tag Organization Schema
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Curon Biopharma
Curon Biopharma is a Healthcare company.
Dizal Pharma
Dizal Pharma is a research-based biotechnology company.
GemPharmatech
GemPharmatech is a biotechnology firm.
Genesis Healthcare
Genesis Healthcare is a Japanese genetic testing company.
Hangzhou Just Biotherapeutics (Just China)
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Jinxin Fertility
Jinxin Fertility is a Chinese fertility services provider.
KBP Biosciences
A multinational clinical stage biotechnology company.
Neumora Therapeutics
Neumora Therapeutics operates as a clinical-stage biotechnology company.
Nymox Pharmaceutical
Nymox Pharmaceutical is a biopharmaceutical company.
Current Employees Featured
Founder
Stock Details
Investors List
Homsun Capital
Homsun Capital investment in Series D - Asieris Pharmaceuticals
TriWise Capital
TriWise Capital investment in Series D - Asieris Pharmaceuticals
China Highrun Capital Limited
China Highrun Capital Limited investment in Series D - Asieris Pharmaceuticals
SAIC Capital
SAIC Capital investment in Series D - Asieris Pharmaceuticals
YF Capital
YF Capital investment in Series D - Asieris Pharmaceuticals
Gopher Asset Management
Gopher Asset Management investment in Series D - Asieris Pharmaceuticals
C&D Emerging Investment
C&D Emerging Investment investment in Series D - Asieris Pharmaceuticals
CICC
CICC investment in Series D - Asieris Pharmaceuticals
Haoshuo Zhier Fund
Haoshuo Zhier Fund investment in Series D - Asieris Pharmaceuticals
Xiamen C&D Corporation
Xiamen C&D Corporation investment in Series D - Asieris Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2024-01-09 | Asieris Pharmaceuticals Appoints Sophia Cao as Senior Vice President and Head of the Women's Health Business Unit |
Official Site Inspections
http://www.asieris.com Semrush global rank: 6.22 M Semrush visits lastest month: 1.08 K
- Host name: 185.166.146.217.static.a2webhosting.com
- IP address: 185.166.146.217
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Asieris Pharmaceuticals"
Home - Asieris Pharmaceuticals
Asieris Unveils Results for the First Time at 2024 IPVC the Analysis of the of HPV Clearance Rate for Different HPV Types and Different Follow-up Times of the Non-Surgical Treatment for Cervical HSIL Product APL-1702 Clinical Study โฆSee details»
Asieris Pharmaceuticals - Crunchbase Company Profile โฆ
Asieris Pharmaceuticals may be growing as evidenced by the establishment of a new Women's Health Business Unit, which indicates an expansion of operations into a new healthcare segment. The appointment of a leader to head this unit โฆSee details»
Asieris Pharmaceuticals - Overview, News & Similar companies
Asieris adheres to a growth strat egy driven by in-house research and development, supplemented by in-licensing, to rapidly establish a leadership position in the field of focus. โฆSee details»
Asieris Pharmaceuticals - LinkedIn
Asieris Pharmaceuticals, founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases.See details»
Investors - Asieris Pharmaceuticals
Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment โฆSee details»
Asieris Releases 2022 Annual Report: Makes Steady Progress in its ...
Apr 17, 2023 Asieris Pharmaceuticals (688176.SH), founded in March 2010, is a global biopharma company specializing in the discovery, development and commercialization of โฆSee details»
Asieris Pharmaceuticals - Craft
Asieris Pharmaceuticals is a biotech company that specializes in the development and commercialization of pharmaceutical drugs. It aims to provide treatment for genitourinary โฆSee details»
Kevin Pan โ CEO, Asieris, China - PharmaBoardroom
Oct 16, 2019 Kevin Pan, CEO of Asieris, shares the origins behind the companyโs distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative โฆSee details»
Asieris Pharmaceuticals Announces 2021 Annual Report: Steady โฆ
Apr 14, 2022 Asieris Pharmaceuticals maintained a healthy financial position while steadily advancing various new drug R&D projects. In 2021, the R&D expenditures amounted to RMB โฆSee details»
Asieris Pharmaceuticals Unveils 2023 Annual Report, Core Product โฆ
Apr 17, 2024 Asieris boasts a robust pipeline now consisting of 13 products and 16 ongoing research projects. ... These findings were featured in oral presentations at the 2024 European โฆSee details»
Enhancing Leadership in Gynecology, Asieris Pharmaceuticals โฆ
Jan 9, 2024 Asieris Pharmaceuticals (Stock code ๏ผ688176.SH) has announced its set-up of the Women's Health Business Unit for commercialization. This strategic move is designed to โฆSee details»
Asieris Pharmaceuticals Releases 2024 Semi-Annual Report, โฆ
SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2024 Semi-Annual Report, showcasing a strong growth momentum. The launch of its blockbuster โฆSee details»
Highlights of Asieris Pharmaceuticals 2022 Annual Report
Apr 17, 2023 Highlights of Asieris Pharmaceuticals 2022 Annual Report. Skip to content. Search. Search. Close this search box. Menu. Home > Investor Announcements > Highlights โฆSee details»
Asieris Announces the World's First Patient Dose Administered in ...
Jan 4, 2022 Asieris Pharmaceuticals, founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major โฆSee details»
News & Media - Asieris Pharmaceuticals
Oct 21, 2024 Asieris Received FDA IND Approval for a Novel USP1 Inhibitor for the Treatment of Advanced Solid Tumors . 2024. 2023. 2022. 2021. 2020. 2019. 2024. October 22, 2024 . โฆSee details»
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, โฆ
Aug 22, 2023 Asieris has built a robust portfolio, including oral therapeutic drug APL-1202 (Vesique®), imaging agent APL-1706 (Hexvix®), and disposable bladder endoscope APLD โฆSee details»
Asieris Showcases Worldโs 1st Product for Non-Invasive Treatment โฆ
Nov 5, 2024 Asieris also debuted several cutting-edge products and technologies at the CIIE, including the worldโs first non-invasive treatment for precancerous cervical lesions, a โฆSee details»
Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual โฆ
Aug 24, 2022 Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative โฆSee details»
Photocure Partner Asieris to present First-ever Results of the ...
Feb 22, 2024 Photocure developed Cevira through Phase 1 and Phase 2 trials, and the global rights for development and commercialization were out-licensed to Asieris Meditech Co., Ltd in โฆSee details»